Mainstream

Arcturus Up 9% As Phase 2 Dosing Begins For Mrna Asset For Cystic Fibrosis

Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis

Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis

Post ContentarctRead More

You might also be interested in reading Ryanair cuts passenger forecasts amid delays in receiving Boeing planes.

January 7, 2025
In Mainstream